Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

New muscarinic compounds from Alcon especially useful for Rx of glaucoma

July 29, 1999

New agents for glaucoma disclosed by Alcon in recent patent literature

July 27, 1999

Sunrise LTK System not recommended for FDA approval

July 26, 1999

Alcon's new prostaglandin analogues for glaucoma

July 26, 1999

FDA Advisory Committee votes against recommending Allergan therapy for dry eye disease

July 26, 1999

FDA approves same-day, second-eye treatment with Sunrise LTK system

July 15, 1999

More on PEDF: protein also has ophthalmic indications

July 13, 1999

CAT gets U.K. approval to begin phase II trials of novel glaucoma treatment

July 12, 1999

Allergan ciclosporin NDA up for review this month by advisory committee

July 12, 1999

Midostaurin is a promising new agent for preventing vision loss

July 9, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...